# | Title | Journal | Year | Citations |
---|
1 | Mitochondrial membrane permeabilization and cell death during myocardial infarction: roles of calcium and reactive oxygen species | Future Cardiology | 2012 | 238 |
2 | From particles to patients: oxidative stress and the cardiovascular effects of air pollution | Future Cardiology | 2012 | 212 |
3 | Type-2 diabetes mellitus and cardiovascular disease | Future Cardiology | 2018 | 197 |
4 | PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ | Future Cardiology | 2017 | 183 |
5 | Kounis syndrome: a new twist on an old disease | Future Cardiology | 2011 | 168 |
6 | Rho kinase as a therapeutic target in cardiovascular disease | Future Cardiology | 2011 | 155 |
7 | Astaxanthin, oxidative stress, inflammation and cardiovascular disease | Future Cardiology | 2009 | 145 |
8 | Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease | Future Cardiology | 2010 | 122 |
9 | Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation | Future Cardiology | 2015 | 121 |
10 | PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α | Future Cardiology | 2017 | 120 |
11 | Exercise-based cardiac rehabilitation in patients with coronary heart disease: meta-analysis outcomes revisited | Future Cardiology | 2012 | 116 |
12 | Cardiotoxicity in childhood cancer survivors: strategies for prevention and management | Future Cardiology | 2012 | 116 |
13 | The golden age of minimally invasive cardiothoracic surgery: current and future perspectives | Future Cardiology | 2011 | 112 |
14 | Targeting cardiovascular disease with novel SIRT1 pathways | Future Cardiology | 2012 | 102 |
15 | Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia | Future Cardiology | 2005 | 85 |
16 | Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies | Future Cardiology | 2013 | 78 |
17 | Atrial fibrillation and ethnicity: the known, the unknown and the paradox | Future Cardiology | 2009 | 71 |
18 | Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program | Future Cardiology | 2018 | 70 |
19 | Stem cells in cardiac repair | Future Cardiology | 2011 | 67 |
20 | Role of NADPH oxidase in atherosclerosis | Future Cardiology | 2009 | 64 |
21 | A life course approach to cardiovascular aging | Future Cardiology | 2015 | 64 |
22 | Plasmonic photothermal therapy of atherosclerosis with nanoparticles: long-term outcomes and safety in NANOM-FIM trial | Future Cardiology | 2017 | 64 |
23 | The future of aerobic exercise testing in clinical practice: is it the ultimate vital sign? | Future Cardiology | 2010 | 62 |
24 | Using ST2 in cardiovascular patients: a review | Future Cardiology | 2014 | 59 |
25 | ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks | Future Cardiology | 2015 | 57 |
26 | The future of warfarin pharmacogenetics in under-represented minority groups | Future Cardiology | 2012 | 56 |
27 | COVID-19 outbreak: impact of the quarantine-induced stress on cardiovascular disease risk burden | Future Cardiology | 2020 | 55 |
28 | PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016 | Future Cardiology | 2012 | 54 |
29 | Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course | Future Cardiology | 2012 | 54 |
30 | Mesenchymal stromal cells for cardiovascular repair: current status and future challenges | Future Cardiology | 2009 | 53 |
31 | Pulmonary hypertension in congenital heart disease | Future Cardiology | 2018 | 53 |
32 | Novel imaging techniques for diffuse myocardial fibrosis | Future Cardiology | 2011 | 52 |
33 | Bacterial invasion of vascular cell types: vascular infectology and atherogenesis | Future Cardiology | 2012 | 52 |
34 | Cardiovascular dysfunctions and sympathovagal imbalance in hypertension and prehypertension: physiological perspectives | Future Cardiology | 2013 | 52 |
35 | Mechanisms of myocardial ischemia–reperfusion injury and the cytoprotective role of minocycline: scope and limitations | Future Cardiology | 2015 | 52 |
36 | Elinogrel: pharmacological principles, preclinical and early phase clinical testing | Future Cardiology | 2010 | 51 |
37 | Should torsemide be the loop diuretic of choice in systolic heart failure? | Future Cardiology | 2012 | 51 |
38 | Estrogen, aging and the cardiovascular system | Future Cardiology | 2009 | 49 |
39 | The epicardium as a candidate for heart regeneration | Future Cardiology | 2012 | 49 |
40 | Alcohol consumption and cardiovascular risk: mechanisms of action and epidemiologic perspectives | Future Cardiology | 2009 | 48 |
41 | The obesity paradox and outcome in heart failure: is excess bodyweight truly protective? | Future Cardiology | 2010 | 48 |
42 | Reviewing peripartum cardiomyopathy: current state of knowledge | Future Cardiology | 2009 | 47 |
43 | New directions in antiarrhythmic drug therapy for atrial fibrillation | Future Cardiology | 2013 | 47 |
44 | Depression and anxiety in patients with chronic heart failure | Future Cardiology | 2018 | 47 |
45 | Fetal cardiac screening and variation in prenatal detection rates of congenital heart disease: why bother with screening at all? | Future Cardiology | 2012 | 46 |
46 | Air embolism: diagnosis and management | Future Cardiology | 2017 | 45 |
47 | Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors | Future Cardiology | 2011 | 43 |
48 | Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework | Future Cardiology | 2011 | 43 |
49 | Effects of caffeine and coffee consumption on cardiovascular disease and risk factors | Future Cardiology | 2007 | 40 |
50 | Sudden cardiac death in COVID-19 patients, a report of three cases | Future Cardiology | 2021 | 40 |